Yiwei Li

16.5k total citations · 2 hit papers
135 papers, 11.3k citations indexed

About

Yiwei Li is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Yiwei Li has authored 135 papers receiving a total of 11.3k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Molecular Biology, 51 papers in Oncology and 50 papers in Cancer Research. Recurrent topics in Yiwei Li's work include MicroRNA in disease regulation (26 papers), Cancer-related Molecular Pathways (19 papers) and Epigenetics and DNA Methylation (16 papers). Yiwei Li is often cited by papers focused on MicroRNA in disease regulation (26 papers), Cancer-related Molecular Pathways (19 papers) and Epigenetics and DNA Methylation (16 papers). Yiwei Li collaborates with scholars based in United States, China and Japan. Yiwei Li's co-authors include Fazlul H. Sarkar, Dejuan Kong, Zhiwei Wang, Aamir Ahmad, Sanjeev Banerjee, Asfar S. Azmi, Shadan Ali, Bin Bao, Zhiwei Wang and Philip A. Philip and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Yiwei Li

135 papers receiving 11.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intratumoral Balance of Regulatory and Cytotoxic T Cells Is Associated With Prognosis of Hepatocellular Carcinoma After Resection

2007 913 citations Yiwei Li et al. Journal of Clinical Oncology profile →
Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway

2009 527 citations Zhiwei Wang, Yiwei Li et al. profile →

Peers

Countries citing papers authored by Yiwei Li

Since Specialization

Citations

This map shows the geographic impact of Yiwei Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yiwei Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yiwei Li more than expected).

Fields of papers citing papers by Yiwei Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yiwei Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yiwei Li. The network helps show where Yiwei Li may publish in the future.

Co-authorship network of co-authors of Yiwei Li

This figure shows the co-authorship network connecting the top 25 collaborators of Yiwei Li. A scholar is included among the top collaborators of Yiwei Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yiwei Li. Yiwei Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Renal clearable CRISPR nanosensor targeting mitochondrial DNA mutation for noninvasive monitoring of tumor progression and metastasis 2025 ·Science Advances ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Yongyuan Zhang, Jingjing Zhang, (unknown), Wen Zhao, (unknown), Yiwei Li, (unknown), Kaixiang Zhang	1
2	Butyrate alleviates alcoholic liver disease-associated inflammation through macrophage regulation and polarization via the HDAC1/miR-155 axis 2024 ·International Immunopharmacology ·Lina Zhang, Zhiguo Ma, Xiaoxu Zhang, (unknown), Jing Wang, Wenyan Tian, Yi Ren, Yajuan Liu, Ting Wang, Yiwei Li, Yuanyuan Liu, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Shaoqi Yang, Hao Wang	10
3	Long non-coding RNAs are involved in the crosstalk between cancer-associated fibroblasts and tumor cells 2024 ·Frontiers in Immunology ·(unknown), (unknown), Yiwei Li, (unknown), Xiaonan Liu, Xiangyu Tian, Zhi Sun, Mohammad Tabish, (unknown), Kuisheng Chen, Miaomiao Sun	4
4	A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic adenocarcinoma. 2023 ·Journal of Clinical Oncology ·Mandana Kamgar, Husain Yar Khan, Amro Aboukameel, (unknown), Brian Y. Chung, Anikó Szabó, Yiwei Li, Mohammed Najeeb Al Hallak, (unknown), Ben George, Kathleen K. Christians, Douglas B. Evans, Susan Tsai, Beth Erickson, (unknown), Asfar S. Azmi, William A. Hall	1
5	Meeting report: Advancing accelerated regulatory review with Real-Time Oncology Review (RTOR), Project Orbis, and the Product Quality Assessment Aid 2022 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), Nina S. Cauchon, Xiaohong Chen, (unknown), (unknown), Tao Li, Yiwei Li, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Kin Tang, Timothy Watson	2
6	Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers 2022 ·Cancer Research Communications ·Husain Yar Khan, Misako Nagasaka, Yiwei Li, Amro Aboukameel, Md. Hafiz Uddin, Rachel Sexton, (unknown), (unknown), Mohammed Najeeb Al Hallak, Steve Kim, (unknown), Yosef Landesman, Hirva Mamdani, Dipesh Uprety, Philip A. Philip, Ramzi M. Mohammad, Anthony F. Shields, Asfar S. Azmi	21
7	Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy 2022 ·Advances in Radiation Oncology ·Husain Yar Khan, Mandana Kamgar, Amro Aboukameel, (unknown), Brian Y. Chung, Yiwei Li, Mohammed Najeeb Al Hallak, Philip A. Philip, Susan Tsai, (unknown), William A. Hall, Asfar S. Azmi	13
8	PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus 2021 ·Molecular Cancer Therapeutics ·(unknown), Md. Hafiz Uddin, Mohammed Najeeb Al Hallak, Amro Aboukameel, Yiwei Li, Steve Kim, (unknown), Gregory Dyson, Erkan Baloglu, William Senapedis, Yosef Landesman, Kay‐Uwe Wagner, Nerissa T. Viola, Bassel F. El‐Rayes, Philip A. Philip, Ramzi M. Mohammad, Asfar S. Azmi	16
9	KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? 2020 ·Cancer Treatment Reviews ·Misako Nagasaka, Yiwei Li, Ammar Sukari, Sai‐Hong Ignatius Ou, Mohammed Najeeb Al Hallak, Asfar S. Azmi	147
10	The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness 2012 ·Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·Bin Bao, Asfar S. Azmi, Shadan Ali, Aamir Ahmad, Yiwei Li, Sanjeev Banerjee, Dejuan Kong, Fazlul H. Sarkar	155
11	Metformin Inhibits Cell Proliferation, Migration and Invasion by Attenuating CSC Function Mediated by Deregulating miRNAs in Pancreatic Cancer Cells 2011 ·Cancer Prevention Research ·Bin Bao, Zhiwei Wang, Shadan Ali, Aamir Ahmad, Asfar S. Azmi, Sanila H. Sarkar, Sanjeev Banerjee, Dejuan Kong, Yiwei Li, (unknown), Fazlul H. Sarkar	286
12	Inactivation of AR/TMPRSS2-ERG/Wnt Signaling Networks Attenuates the Aggressive Behavior of Prostate Cancer Cells 2011 ·Cancer Prevention Research ·Yiwei Li, Dejuan Kong, Zhiwei Wang, Aamir Ahmad, Bin Bao, Subhash Padhyé, Fazlul H. Sarkar	33
13	5-Lipoxygenase-Activating Protein (FLAP) Inhibitors. Part 4: Development of 3-[3- tert -Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1 H -indol-2-yl]-2,2-dimethylpropionic Acid (AM803), a Potent, Oral, Once Daily FLAP Inhibitor 2011 ·Journal of Medicinal Chemistry ·Nicholas Stock, Gretchen Bain, (unknown), Yiwei Li, (unknown), Jeffrey Roppe, Angelina M. Santini, Janice Darlington, Pat Prodanovich, Christopher D. King, Christopher Baccei, Catherine Lee, Haojing Rong, Charles W. Chapman, (unknown), (unknown), Lucia Correa, John H. Hutchinson, Jilly F. Evans, Peppi Prasit	39
14	Pancreatic cancer: understanding and overcoming chemoresistance 2010 ·Nature Reviews Gastroenterology & Hepatology ·Zhiwei Wang, Yiwei Li, Aamir Ahmad, Sanjeev Banerjee, Asfar S. Azmi, Dejuan Kong, Fazlul H. Sarkar	284
15	Pharmacological Characterization of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103), a Novel Selective 5-Lipoxygenase-Activating Protein Inhibitor That Reduces Acute and Chronic Inflammation 2009 ·Journal of Pharmacology and Experimental Therapeutics ·Daniel S. Lorrain, Gretchen Bain, Lucia Correa, Charles W. Chapman, (unknown), Angelina M. Santini, Pat Prodanovich, Janice Darlington, John H. Hutchinson, Christopher D. King, Catherine Lee, Christopher Baccei, Yiwei Li, (unknown), Jilly F. Evans	11
16	NF-κB Signaling Pathway and Its Therapeutic Implications in Human Diseases 2008 ·International Reviews of Immunology ·Fazlul H. Sarkar, Yiwei Li, Zhiwei Wang, Dejuan Kong	189
17	MicroRNA and Cancer: Tiny Molecules with Major Implications 2008 ·Current Genomics ·Timothy VandenBoom, Yiwei Li, Philip A. Philip, Fazlul H. Sarkar	62
18	Regulation of Microtubule, Apoptosis, and Cell Cycle-Related Genes by Taxotere in Prostate Cancer Cells Analyzed by Microarray 2004 ·Neoplasia ·Yiwei Li, Xingli Li, Maha Hussain, Fazlul H. Sarkar	48
19	Gene Expression Profiles of Genistein-Treated PC3 Prostate Cancer Cells 2002 ·Journal of Nutrition ·Yiwei Li, Fazlul H. Sarkar	96
20	Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol. 2000 ·PubMed ·Yiwei Li, (unknown), Samir Alhasan, Adrian M. Senderowicz, Fazlul H. Sarkar	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact